Cargando…
An Update on the Current State of Management and Clinical Trials for IgA Nephropathy
IgA nephropathy remains the most common primary glomerular disease worldwide. It affects children and adults of all ages, and is a leading cause of end-stage kidney disease, making it a considerable public health issue in many countries. Despite being initially described over 50 years ago, there are...
Autores principales: | Cheung, Chee Kay, Rajasekaran, Arun, Barratt, Jonathan, Rizk, Dana V. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8200196/ https://www.ncbi.nlm.nih.gov/pubmed/34200024 http://dx.doi.org/10.3390/jcm10112493 |
Ejemplares similares
-
New strategies and perspectives on managing IgA nephropathy
por: Selvaskandan, Haresh, et al.
Publicado: (2019) -
New insights into the pathogenesis of IgA nephropathy
por: Yeo, See Cheng, et al.
Publicado: (2017) -
Monitoring Immune Responses in IgA Nephropathy: Biomarkers to Guide Management
por: Selvaskandan, Haresh, et al.
Publicado: (2020) -
New Insights into the Pathogenesis and Treatment Strategies in IgA Nephropathy
por: Scionti, Katrin, et al.
Publicado: (2021) -
Targeting the Endothelin A Receptor in IgA Nephropathy
por: Kohan, Donald E., et al.
Publicado: (2023)